Johnson & Johnson subsidiary Janssen has presented promising results from two Phase III...
- Janssen’s Darzalex outperforms standard of care in newly diagnosed multiple myeloma
- ViiV submits NDA for drug indicated for multi-drug resistant HIV
- Pharma Technology Focus: improving public relations
- Promising results for Novartis’s Entresto in HFpEF sub-populations
- Cancer drug discovery: unravelling the mysteries of halichondrin
Janssen’s Darzalex outperforms standard of care in newly diagnosed multiple myeloma
Johnson & Johnson subsidiary Janssen has presented promising results from two Phase III trials of Darzalex (daratumumab) in newly diagnosed multiple myeloma patients who are ineligible for surgery or high-dose chemotherapy.
ViiV submits NDA for drug indicated for multi-drug resistant HIV
ViiV Healthcare has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its first-in-class human immunodeficiency virus (HIV) drug fostemsavir.
ImCheck raises Series B funds to develop gamma delta therapies
French biotech firm ImCheck Therapeutics has raised $53m (€48m) in a Series B funding round to develop its gamma delta (γδ) T-cell-based antibodies to treat cancer and autoimmune disorders.
Roche secures FDA approval for Tecentriq combination in lung cancer
Roche has received the US Food and Drug Administration (FDA) approval to use Tecentriq (atezolizumab) plus Abraxane and carboplatin chemotherapy to treat non-small cell lung cancer (NSCLC) patients.
Genentech gets FDA priority review status for risdiplam in SMA
Roche unit Genentech has secured priority review status from the US Food and Drug Administration (FDA) for risdiplam to treat spinal muscular atrophy (SMA).
ViiV to develop bNAb candidate to treat and prevent HIV
ViiV Healthcare has agreed to develop an investigational broadly neutralising antibody (bNAb) N6LS to treat and prevent human immunodeficiency virus 1 (HIV-1) infection.
Pharma Technology Focus: improving public relations
In this issue: PR in pharma, paediatric drug development, repatriating API manufacturing, the Irish pharma juggernaut, bias in cancer drug trials, and much more
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.